References
- International Agency for Research on Cancer (IARC). Latest world cancer statistics, Global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast must be addressed. Lyon, France: International Agency for Research on Cancer (IARC), World Health Organization (WHO), 2013. http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf. Accessed July 18, 2014
- International Agency for Research on Cancer (IARC), World Health Organization (WHO). Fact Sheets by Cancer - Breast Cancer: estimated incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer (IARC), World Health Organization (WHO), 2014. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed July 18, 2014
- Brouckaert O, Laenen A, Vanderhaegen J, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 2012;23:2578-84
- Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012;21:50-7
- Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502
- Voduc KD, Cheang MCU, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91
- Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13
- Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer v2.2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 27, 2014
- Johnston SRD. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-87
- Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22
- National Institute for Health and Care Excellence. Advanced breast cancer: chemotherapy and biological therapy. Manchester, UK: National Institute for Health and Care Excellence, 2013. http://pathways.nice.org.uk/pathways/advanced-breast-cancer. Accessed March 24, 2014
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
- Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84
- U.S. Food and Drug Administration. FDA approves Afinitor for advanced breast cancer. Silver Spring, MD: U.S. Food and Drug Administration, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm. Accessed March 24, 2014
- Newswire Canada. Health Canada Approves (Pr)AFINITOR* in advanced breast cancer for women battling this disease. Dorval, QC, Canada: CNW Group Ltd, 2013. http://www.newswire.ca/en/story/1099655/health-canada-approves-pr-afinitor-in-advanced-breast-cancer-for-women-battling-this-disease. Accessed July 18, 2014
- Novartis Pharmaceutical Corporation. Novartis drug Afinitor® approved by European Commission to treat patients with the most common form of advanced breast cancer. Basel, Switzerland: Novartis Pharmaceutical Corporation, 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1630327.shtml. Accessed March 24, 2014
- European Medicines Agency. AFINITOR. London, UK: European Medicines Agency, 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001038/human_med_000633.jsp&mid=WC0b01ac058001d124. Accessed July 18, 2014
- Schott AF. Systemic treatment of metastatic breast cancer in women: chemotherapy. In: Basow DS, ed. Waltham, MA: Wolter Kluwer Health, 2014. http://www.uptodate.com/contents/systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy. Accessed March 27, 2014
- Chan A, Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer 2009;45:2253-65
- Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004;31(1 Suppl):S149-61
- Bergh J, Jönsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-81
- Hansen RN, Brammer MG, Ramsey SD, et al. The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine. J Clin Oncol 2013;31:abstr e17527
- Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17
- O’Shaughnessy JA, Kaufmann M, Siedentopf F, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist 2012;17:476-84
- Yardley DA. Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 2009;14:448-55
- Noguchi S, Masuda N, Iwata H, et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 2013;published online 13 February, 2013, doi: 10.1007/s12282-013-0444-8
- European Central Bank (ECB). Statistical Data Warehouse: Consumer price indices. Frankfurt am Main, Germany: European Central Bank, 2014. http://sdw.ecb.europa.eu/browseSelection.do;jsessionid=41F2C7A150E3F9EE64F5B9933DB40AA0?DATASET=0&ADJUSTMENT=S&sfl3=4&ICP_ITEM=000000&sfl4=3&node=2120778. Accessed August 5, 2014
- Hampshire County Council. Retail Prices Index and Consumer Price Index. Winchester, Hampshire, UK: Hampshire County Council, 2014. http://www3.hants.gov.uk/finance/retailpricesindexandconsumerpriceindex.htm. Accessed April 4, 2014
- U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer Price Index (CPI). Washington, DC: 2014. http://www.bls.gov/cpi/home.htm. Accessed April 28, 2014
- USD to EUR Rates on 1/31/2013 - Exchange Rates. MBH Media, 2014. http://www.exchange-rates.org/Rate/USD/EUR/1-31-2013. Accessed April 3, 2014
- Teva Pharmaceuticals USA. Capecitabine. Sellersville, PA: Teva Pharmaceuticals USA, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020896s016lbl.pdf. Accessed April 2, 2014
- Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-61
- Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54
- Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
- O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9
- Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
- Paz-Ares L, García del Muro X, Grande E, et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008;10:831-9
- McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997;15:640-5
- Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6
- Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008;11:791-9
- Nichols GA, Arondekar B, Herman WH. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 2008;14:791-8
- Banz K, Bischoff H, Brunner M, et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 2011;74:529-34
- Lundkvist J, Ekman M, Ericsson SR, et al. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol 2005;75:179-85
- Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11:1-144
- Office for National Statistics (ONS). Price Indices and Inflation: Consumer Prices Index Taxonomy Search Results. Newport, South Wales, UK: Office for National Statistics, 2014. http://www.ons.gov.uk/ons/rel/cpi/consumer-price-indices/december-2012/cpi-and-rpi-reference-tables.xls. Accessed April 4, 2014
- White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999;15:445-58
- Frías C, Cortés J, Seguí MÁ, et al. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. Clin Transl Oncol 2010;12:692-700
- Baena-Cañada JM, Estalella-Mendoza S, González-Guerrero M, et al. [Influence of clinical and biographical factors on the quality of life of women with breast cancer receiving adjuvant chemotherapy]. Rev Calid Asist 26:299–305
- Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol 2014;25:763-73
- Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2014;143:459-67
- Kim MK, Lee J-L, Hyun MS, et al. Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer. Jpn J Clin Oncol 2008;38:64-70
- Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997;15:330-40
- Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-5
- Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 2001;30:146-52
- Ejlertsen B, Jerusalem G, Hurvitz S, et al. everolimus plus exemestane versus everolimus or capecitabine monotherapy in breast cancer: BOLERO-6. St. Gallen International Breast Cancer Conference. St. Gallen, Switzerland; 2013. http://orbi.ulg.ac.be/bitstream/2268/157164/1/St Gall 2013 poster.pdf. Accessed April 3, 2014